Victory Capital Management Inc. Raises Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Victory Capital Management Inc. raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 41.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 123,067 shares of the medical equipment provider's stock after acquiring an additional 35,937 shares during the period. Victory Capital Management Inc. owned about 0.18% of Lantheus worth $12,011,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of LNTH. State of Michigan Retirement System lifted its stake in Lantheus by 0.6% in the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after buying an additional 100 shares during the period. Signaturefd LLC raised its position in Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 116 shares during the last quarter. Avantax Advisory Services Inc. raised its position in Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after buying an additional 132 shares during the last quarter. Foundry Partners LLC raised its position in Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after buying an additional 133 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Lantheus by 2.1% in the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 139 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Trading Up 2.8%

LNTH traded up $2.00 during midday trading on Friday, reaching $72.93. 615,452 shares of the company's stock traded hands, compared to its average volume of 1,083,256. The firm has a fifty day moving average of $78.06 and a two-hundred day moving average of $88.72. The stock has a market capitalization of $5.05 billion, a price-to-earnings ratio of 20.72 and a beta of 0.12. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. Lantheus Holdings, Inc. has a 52 week low of $69.12 and a 52 week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same quarter last year, the company posted $1.69 EPS. The firm's revenue was up .8% on a year-over-year basis. On average, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Truist Financial lowered their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. B. Riley lowered their target price on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $131.20.

Insider Buying and Selling at Lantheus

In related news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.